Who are High Dose Colistin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Colistin/Polymyxin B + Sulbactam, Ceftazidime-avibactam + Colistin/Polymyxin B, Standard Dose Colistin, Polymyxin e, Colistimethate sodium for injection, polymixin/bacitracin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-dose-colistin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

High Dose Colistin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Dose Colistin (High Dose Colistin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polymyxin antibiotic. Area: Infectious Disease.

marketed Polymyxin antibiotic Bacterial lipopolysaccharide (LPS) and outer membrane Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

High Dose Colistin (High Dose Colistin) — King Saud Medical City. Colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and causing leakage of cellular contents.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
High Dose Colistin TARGET	High Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharide (LPS) and outer membrane
Colistin/Polymyxin B + Sulbactam	Colistin/Polymyxin B + Sulbactam	National University of Singapore	marketed	Polymyxin antibiotic + β-lactamase inhibitor combination	Bacterial cell membrane (polymyxins); bacterial β-lactamases (sulbactam)
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
Standard Dose Colistin	Standard Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Polymyxin e	Polymyxin e	Mahmoud I Mostafa	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Colistimethate sodium for injection	Colistimethate sodium for injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Polymyxin antibiotic	Bacterial lipopolysaccharide and phospholipid membranes
polymixin/bacitracin	polymixin/bacitracin	Vanderbilt University Medical Center	phase 3	Polymyxin antibiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polymyxin antibiotic class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
King Saud Medical City · 2 drugs in this class
Hospitales Universitarios Virgen del Rocío · 1 drug in this class
Mahmoud I Mostafa · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High Dose Colistin — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-colistin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing